In this study, we utilize a Methylation Assay Kit designed explicitly for the Twist1/Vimentin gene (produced by Jiangsu MicroDiag Biomedicine Co., Ltd., China), intending to assess its diagnostic precision and clinical applicability in patients with bladder cancer. This evidence concerns the gene VIM and urinary bladder carcinoma.